<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136600</url>
  </required_header>
  <id_info>
    <org_study_id>EGFR-GC</org_study_id>
    <nct_id>NCT04136600</nct_id>
  </id_info>
  <brief_title>EGFR Monoclonal Antibody for Advanced Gastric Cancer</brief_title>
  <official_title>A Study of EGFR Monoclonal Antibody (Cetuximab/Nimotuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With EGFR-amplification Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate efficacy and safety of EGFR monoclonal antibody
      (Cetuximab/Nimotuzumab) in combination with a chemotherapy in gastric cancer patients with
      EGFR amplification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This parallel, randomized, open-label, single-centre study will evaluate the effect on
      overall survival of EGFR monoclonal antibody (Cetuximab/Nimotuzumab) in combination with a
      chemotherapy compared to the chemotherapy alone in patients with EGFR-amplication advanced
      gastric cancer. Cetuximab will be administered as intravenous infusion of 500 mg/m2 (BSA)
      every 3 weeks, while nimotuzumab will be administered as intravenous infusion of 400mg every
      week. The chemotherapy consists of a combination of 12 cycles of mFOLFOX-6, 6-8 cycles of
      SOX, 6-8 cycles of CapOX. Treatment with cetuximab/nimotuzumab will continue until disease
      progression. The target sample size is 50-100 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Evaluation of tumor burden until first documented progress through study completion, an average of 2 years</time_frame>
    <description>Time from treatment beginning until disease progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Evaluation of tumor burden through study completion, an average of 2 years</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of treatment beginning until the date of death from any cause through study completion, an average of 2 years</time_frame>
    <description>Time from treatment beginning until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>Incidence of Treatment-related adverse Events through study completion, an average of 2 years</time_frame>
    <description>Incidence of Treatment-related adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Cetuximab</condition>
  <condition>Nimotuzumab</condition>
  <arm_group>
    <arm_group_label>EGFR antibody arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a dose of 500 mg/m2 Cetuximab iv on Day 1 of cycle every 3 weeks, or 400mg Nimotuzumab on Day 1 of cycle, every week, until disease progression. 12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA&gt;1.5, 50 mg for 1.5&gt;BSA&gt;1.25 , 40mg for BSA&lt;1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 cycles of mFOLFOX (5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly). 6-8 cycles of CapOX (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks). 6-8 cycles of SOX (S-1, 60mg for BSA&gt;1.5, 50 mg for 1.5&gt;BSA&gt;1.25 , 40mg for BSA&lt;1.25 po twice daily for 14 days every 3 weeks + oxaliplatin 135mg/m2 every 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR antibody and Chemotherapy</intervention_name>
    <description>Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.
Other Names:
Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression
Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles
Other Names:
5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles
Other Names:
Xeloda Drug: S-1 S-1: 60mg for BSA&gt;1.5, 50 mg for 1.5&gt;BSA&gt;1.25 , 40mg for BSA&lt;1.25 po twice daily for 14 days every 3 weeks, for 6 cycles
Other Names:
S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;</description>
    <arm_group_label>EGFR antibody arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles
Other Names:
5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles
Other Names:
Xeloda Drug: S-1 S-1: 60mg for BSA&gt;1.5, 50 mg for 1.5&gt;BSA&gt;1.25 , 40mg for BSA&lt;1.25 po twice daily for 14 days every 3 weeks, for 6 cycles
Other Names:
S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt;=18 years of age

          -  Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or
             gastro-esophageal junction Adenocarcinoma

          -  EGFR-Amplification tumors (Copy Number&gt;=5 for tissue or blood Next Generation
             Sequence)

          -  Expected survival ≥ 3 month;

          -  ECOG / PS score: 0-2;

          -  the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109
             / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of normal (ULN); Liver ALT and
             AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 × ULN; Serum Cr ≤ 1 × ULN,
             endogenous creatinine clearance ≥50ml/min;

        Exclusion Criteria:

          -  Previous chemotherapy for advanced/metastatic disease;

          -  Lack of physical integrity of the upper gastrointestinal tract, or malabsorption
             syndrome;

          -  History of cardiac disease;

          -  Dyspnoea at rest, due to complications of advanced malignancy or other disease, or
             patients who require supportive oxygen therapy;

          -  Patient can not comply with research program requirements or follow-up;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Jiao</last_name>
      <phone>+86-13817797639</phone>
      <email>13817797639@139.com</email>
    </contact>
    <investigator>
      <last_name>Yuan-Sheng Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Yuan-Sheng Zang</investigator_full_name>
    <investigator_title>Department Head</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

